Phase 3, single-center, sequential and parallel-group, double-blind, randomized study evaluating the efficacy and safety of Fexofenadine Hydrochloride 180 mg (Allegra®/Telfast®) versus placebo in subjects suffering from seasonal Allergic Rhinitis with symptoms aggravated in presence of pollutants

oleh: Anne K. Ellis, Margarita Murrieta-Aguttes, Sandy Furey, Christopher Carlsten

Format: Article
Diterbitkan: Elsevier 2020-08-01

Deskripsi

No description available for this item.